A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

NCT02511132 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Ewing's Sarcoma

Interventions

BIOLOGICAL: Vigil
DRUG: Temozolomide
DRUG: Irinotecan
DRUG: Gemcitabine
DRUG: Docetaxel

Sponsor

Gradalis, Inc.